Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech ...
Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today announced positive interim results from its ongoing POLARIS ...
At the 2025 American Epilepsy Society Annual Meeting, Stoke Therapeutics and Biogen presented data supporting the potential of zorevunersen as a disease-modifying treatment for Dr ...
Detailed price information for Stoke Therapeutics Inc (STOK-Q) from The Globe and Mail including charting and trades.
Xenon Pharmaceuticals (XENE) announced new data highlighting its commitment in epilepsy, including interim 48-month data from its ongoing X-TOLE ...
The Phase III, open-label extension study suggests EPX-100 has a “positive” risk/benefit profile for the treatment of Dravet ...
The MarketWatch News Department was not involved in the creation of this content.-- Phase 3 CDKL5 deficiency disorder (CDD) results: UCB shares 21 scientific abstracts, including ...
Discover Stoke Therapeutics' promising RNA therapies and market outlook. Learn the risks and commercial potential before investing in STOK shares.
"I dropped onto the sidewalk, my arms wrapped around my bent knees. 'Take him inside, don’t let him see me,' I blurted out.” ...
PsychoGenics has signed on with Italy's Iama Therapeutics to run a preclinical study as part of an effort to identify and develop drug candidates to treat Dravet syndrome. Under the agreement, the U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback